Methods and Study Design of KEYNOTE-522 for TNBC
Lajos Pusztai, MD, DPhil, discusses the methods and design of the phase 3 KEYNOTE-522 trial.
Updated Findings From the KEYNOTE-522 trial in TNBC
Lajos Pusztai, MD, DPhil, discusses recent data from the phase 3 KEYNOTE-522 trial of patients with triple-negative breast cancer.
Dr. Pusztai Discusses DNA Abnormalities in Breast Cancer
Lajos Pusztai, MD, PhD, Yale Cancer Center, discusses DNA abnormalities in breast cancer.